OPTIMIZING LENTIVIRAL VECTOR PRODUCTION FOR CELL THERAPIES: ADVANCING MANUFACTURING STRATEGIES AT OMNIABIO

被引：0

作者：

Al Asafen, H. ^{[2
]}

Sudarsan, A. K. ^{[1
]}

Mcleod, A. ^{[2
]}

Kawka, K. ^{[2
]}

Maystrenko, A. ^{[2
]}

Sirskyj, D. ^{[2
]}

Bagheri, M. ^{[3
]}

Attignon, E. ^{[3
]}

Chettiar, D. ^{[1
]}

Beaudette, P. ^{[1
]}

Razvi, A. ^{[2
]}

Patel, N. ^{[1
]}

McNally, K. ^{[4
]}

Gacerez, A. ^{[4
]}

Fardy, M. ^{[4
]}

机构：

[1] Ctr Commercializat Regenerat Med, Toronto, ON, Canada

[2] Cytiva US, Marlborough, MA USA

[3] OmniaBio, Toronto, ON, Canada

[4] Chimera Bioengn, San Francisco, CA USA

来源：

CYTOTHERAPY | 2024年 / 26卷 / 06期

关键词：

lentivirus; bioreactor; process development;

D O I：

暂无

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

1143

引用

页码：E29 / E30

页数：2

共 50 条

[41] Scalable Lentiviral Vector Production Using Stable HEK293SF Producer Cell Lines
Manceur, Aziza P.
Kim, Howard
Misic, Vanja
Andreev, Nadejda
Dorion-Thibaudeau, July
Lanthier, Stephane
Bernier, Alice
Tremblay, Sonia
Gelinas, Anne-Marie
Broussau, Sophie
Gilbert, Renald
Ansorge, Sven
HUMAN GENE THERAPY METHODS, 2017, 28 (06) : 330 - 339
[42] Overview of CAR-T Cell Generation Using Optimized Plasmid Design and Lentiviral Vector Production
Bazzaro, Enzo
Dumont, Maxime
Seiler, Melodie
Lecornez, Leah
Guise, Marine
Klughertz, Lucie
Gueguen, Claire
Julien, Sylvain
MOLECULAR THERAPY, 2024, 32 (04) : 460 - 460
[43] DEVELOPING AN ADAPTABLE MANUFACTURING PLATFORM FOR THE CGMP PRODUCTION OF ALLOGENEIC T-CELL THERAPIES
Klarer, A.
Santiago-Ortiz, J.
Zhao, J.
Xu, F.
Beighley, R.
CYTOTHERAPY, 2021, 23 (05) : S174 - S174
[44] Optimizing and developing a scalable, chemically defined, animal component-free lentiviral vector production process in a fixed-bed bioreactor
Fiol, Carme Ripoll
Collignon, Marie-Laure
Welsh, John
Rafiq, Qasim A.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2023, 30 : 221 - 234
[45] Manufacturing Standards Key to Advancing Cellular and Gene Therapies FDA works with industry on strategies for assuring high-quality regenerative medicines
Wechsler, Jill
BIOPHARM INTERNATIONAL, 2017, 30 (09) : 8 - 9
[46] Continuous Perfusion with a Stable Producer HEK293 Cell Line for Scaling Up Lentiviral Vector Production
Cattaneo, Maurizio
Rodenbrock, Anja
Lanthier, Stephane
Burney, Elodie
Spanjaard, Remco
Manceur, Aziza
MOLECULAR THERAPY, 2020, 28 (04) : 432 - 432
[47] Quasi-perfusion studies for intensified lentiviral vector production using a continuous stable producer cell line
Stibbs, Dale J.
Couto, Pedro Silva
Takeuchi, Yasuhiro
Rafiq, Qasim A.
Jackson, Nigel B.
Rayat, Andrea C. M. E.
MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2024, 32 (02)
[48] Stable lentiviral vector production cell lines yield LVV titres comparable to the four-plasmid process
Tridgett, M.
Mulet, M.
Raghunath, M.
Johny, S. Parokkaran
Ababi, M.
Beveridge, R.
Salkauskaite, I.
Fustinoni, C.
Peckett, M.
Kent, J.
Montgomery, L.
Asatryan, R.
Warelow, T.
Merritt, T.
Ballard, C.
Pahita, E.
Fernandez-Diaz, C.
White, M.
Parker-Manuel, R.
Dong, Y.
Jiang, M.
Cawood, R.
Branciaroli, C.
Patricio, M. I.
Liu, Q.
HUMAN GENE THERAPY, 2024, 35 (3-4) : A125 - A125
[49] Adaptation of a lentiviral vector producer cell line to reduced-serum, suspension culture for large scale production
Townsend, K
Chen, Y
Dayao, J
Farson, D
Miller, WM
Lin, A
MOLECULAR THERAPY, 2004, 9 : S33 - S33
[50] Pushing the right buttons: genetic silencing in producing cell lines to boost lentiviral vector production led to metabolic disfunction counteracting vector requirements
Lopez, C.
Yubero, M. E.
Arbelaiz, A.
Ramirez, J. C.
Albo, C.
HUMAN GENE THERAPY, 2021, 32 (19-20) : A114 - A115

← 1 2 3 4 5 →